ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients.
Najla AldaoudAshley Graboski-BauerNour AbdoSamir Al BashirAshraf O OweisHanadi EbwainiYousef HasenRami AlazabKiril TrpkovPublished in: Research and reports in urology (2019)
Background: High-grade prostatic intraepithelial neoplasia (HGPIN) is the most likely precancerous lesion for prostatic adenocarcinoma (PCa). Recent molecular studies have shown that HGPIN can harbor TMPRSS2-ERG fusion, a genetic marker also associated with PCa, which may provide an additional risk stratification tool for HGPIN, especially when present as an isolated lesion. Our aim was to assess the frequency of HGPIN and ERG expression in a cohort of prostatic needle core biopsies from Jordanian-Arab patients with PCa. Materials and methods: We studied 109 needle core biopsies from patients with PCa. Clinical data, including age and preoperative prostate specific antigen (PSA) level, were obtained from patients' medical records. Results: HGPIN was present in 31 (28.4 %) of the 109 cases. Of the HGPIN cases, 13 (41.9%) expressed ERG immunostain. ERG expression in HGPIN was independent of patient age at presentation (P=0.4), pre-operative PSA (P=0.9), and the grade, using the novel Grade Groups (P=0.5). Conclusion: The frequency of HGPIN in our cohort appears similar to the one found in the Western patient populations and demonstrates a comparable frequency of ERG expression in these lesions.
Keyphrases
- high grade
- prostate cancer
- radical prostatectomy
- poor prognosis
- low grade
- end stage renal disease
- ejection fraction
- ultrasound guided
- newly diagnosed
- case report
- benign prostatic hyperplasia
- healthcare
- peritoneal dialysis
- binding protein
- patient reported outcomes
- long non coding rna
- genome wide
- machine learning
- dna methylation
- rectal cancer
- radiation therapy